ZA200300509B - Method for treating unstable angina pectoris. - Google Patents
Method for treating unstable angina pectoris. Download PDFInfo
- Publication number
- ZA200300509B ZA200300509B ZA200300509A ZA200300509A ZA200300509B ZA 200300509 B ZA200300509 B ZA 200300509B ZA 200300509 A ZA200300509 A ZA 200300509A ZA 200300509 A ZA200300509 A ZA 200300509A ZA 200300509 B ZA200300509 B ZA 200300509B
- Authority
- ZA
- South Africa
- Prior art keywords
- rhdl
- apolipoprotein
- infusion
- administered
- angina pectoris
- Prior art date
Links
- 208000007814 Unstable Angina Diseases 0.000 title claims description 14
- 238000000034 method Methods 0.000 title description 12
- 238000001802 infusion Methods 0.000 claims description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 26
- 230000001154 acute effect Effects 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 11
- 230000008753 endothelial function Effects 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 208000010125 myocardial infarction Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- 238000011321 prophylaxis Methods 0.000 claims description 6
- 108010071619 Apolipoproteins Proteins 0.000 claims description 5
- 102000007592 Apolipoproteins Human genes 0.000 claims description 5
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 4
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 15
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 15
- 229960004373 acetylcholine Drugs 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 15
- 210000000245 forearm Anatomy 0.000 description 15
- 230000000260 hypercholesteremic effect Effects 0.000 description 15
- 206010047141 Vasodilatation Diseases 0.000 description 14
- 230000024883 vasodilation Effects 0.000 description 14
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 12
- 210000003038 endothelium Anatomy 0.000 description 12
- 229940083618 sodium nitroprusside Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 9
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 102000009027 Albumins Human genes 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 238000008214 LDL Cholesterol Methods 0.000 description 7
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 7
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000001361 intraarterial administration Methods 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 230000004141 reverse cholesterol transport Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 208000019553 vascular disease Diseases 0.000 description 3
- 230000000304 vasodilatating effect Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 229940124638 COX inhibitor Drugs 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 206010058990 Venous occlusion Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000011458 pharmacological treatment Methods 0.000 description 2
- -1 phosphatidylcholine Chemical class 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000004218 vascular function Effects 0.000 description 2
- 230000006442 vascular tone Effects 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- JUGOREOARAHOCO-UHFFFAOYSA-M acetylcholine chloride Chemical compound [Cl-].CC(=O)OCC[N+](C)(C)C JUGOREOARAHOCO-UHFFFAOYSA-M 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000011366 aggressive therapy Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000005796 circulatory shock Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000000544 hyperemic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940056984 integrilin Drugs 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000008069 intimal proliferation Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940008255 miochol Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pretreatment Of Seeds And Plants (AREA)
- Flanged Joints, Insulating Joints, And Other Joints (AREA)
- Supports For Pipes And Cables (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10035352A DE10035352A1 (de) | 2000-07-20 | 2000-07-20 | Verfahren zur Behandlung von instabiler Angina pectoris |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200300509B true ZA200300509B (en) | 2004-02-17 |
Family
ID=7649620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200300509A ZA200300509B (en) | 2000-07-20 | 2003-01-20 | Method for treating unstable angina pectoris. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US7053049B2 (fr) |
| EP (1) | EP1303294B1 (fr) |
| JP (1) | JP4928047B2 (fr) |
| KR (2) | KR20070108955A (fr) |
| AT (1) | ATE333887T1 (fr) |
| AU (2) | AU8200401A (fr) |
| CA (1) | CA2418238C (fr) |
| DE (2) | DE10035352A1 (fr) |
| DK (1) | DK1303294T3 (fr) |
| ES (1) | ES2266234T3 (fr) |
| HU (1) | HU230151B1 (fr) |
| IL (2) | IL154006A0 (fr) |
| NO (1) | NO329848B1 (fr) |
| NZ (1) | NZ523784A (fr) |
| PL (1) | PL204406B1 (fr) |
| WO (1) | WO2002007753A2 (fr) |
| ZA (1) | ZA200300509B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007000924A1 (fr) * | 2005-06-28 | 2007-01-04 | Osaka University | Préparation pharmaceutique comprenant une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline et méthode de criblage pour la recherche d'une substance susceptible d'inhiber ou de promouvoir l'activité de la progranuline |
| US7956035B2 (en) * | 2007-03-01 | 2011-06-07 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
| US20090110739A1 (en) * | 2007-05-15 | 2009-04-30 | University Of North Texas Health Science Center At Forth Worth | Targeted cancer chemotherapy using synthetic nanoparticles |
| WO2010057203A2 (fr) | 2008-11-17 | 2010-05-20 | The Board Of Regents Of The University Of Texas System | Particules de hdl pour administration d'acides nucléiques |
| EP2900475B1 (fr) | 2012-09-25 | 2018-03-28 | Hewlett-Packard Development Company, L.P. | Détection de goutte |
| ITMI20131300A1 (it) * | 2013-08-01 | 2015-02-02 | Nobil Bio Ricerche Srl | Composizione per il riempimento di difetti ossei e parodontali |
| US20160346219A1 (en) | 2015-06-01 | 2016-12-01 | Autotelic Llc | Phospholipid-coated therapeutic agent nanoparticles and related methods |
| GB2603950A (en) | 2021-02-22 | 2022-08-24 | Reckitt & Colman Overseas Hygiene Home Ltd | Effervescent germicidal compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5128318A (en) * | 1987-05-20 | 1992-07-07 | The Rogosin Institute | Reconstituted HDL particles and uses thereof |
| CA1335077C (fr) * | 1988-02-08 | 1995-04-04 | Henri Isliker | Mode de fabrication d'apolipoproteines a partir du plasma ou de serum humains |
| EP0543417A1 (fr) * | 1991-11-22 | 1993-05-26 | Lipogenics, Incorporated | Tocotriènols et composés sembles à tocotriènol et méthodes pour leur utilisation |
| US5652339A (en) * | 1993-12-31 | 1997-07-29 | Rotkreuzstiftung Zentrallaboratorium | Method of producing reconstituted lipoproteins |
| JPH10218861A (ja) * | 1997-02-04 | 1998-08-18 | Yamanouchi Pharmaceut Co Ltd | 新規なフェネタノール誘導体又はその塩 |
| US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
| GB9919713D0 (en) * | 1999-08-19 | 1999-10-20 | Queen Mary & Westfield College | New medical use of high density lipoprotein |
| AU777788B2 (en) * | 1999-11-26 | 2004-10-28 | Heart Research Institute Limited, The | Oxidized apolipoproteins and methods of use |
| AUPQ429399A0 (en) | 1999-11-26 | 1999-12-23 | Heart Research Institute, The | Oxidized apolipoproteins and methods of use |
-
2000
- 2000-07-20 DE DE10035352A patent/DE10035352A1/de not_active Ceased
-
2001
- 2001-07-20 WO PCT/EP2001/008425 patent/WO2002007753A2/fr active IP Right Grant
- 2001-07-20 PL PL366395A patent/PL204406B1/pl unknown
- 2001-07-20 US US10/333,212 patent/US7053049B2/en not_active Expired - Lifetime
- 2001-07-20 AT AT01960527T patent/ATE333887T1/de active
- 2001-07-20 KR KR1020077025016A patent/KR20070108955A/ko not_active Application Discontinuation
- 2001-07-20 AU AU8200401A patent/AU8200401A/xx active Pending
- 2001-07-20 DE DE50110552T patent/DE50110552D1/de not_active Expired - Lifetime
- 2001-07-20 DK DK01960527T patent/DK1303294T3/da active
- 2001-07-20 EP EP01960527A patent/EP1303294B1/fr not_active Expired - Lifetime
- 2001-07-20 CA CA2418238A patent/CA2418238C/fr not_active Expired - Fee Related
- 2001-07-20 NZ NZ523784A patent/NZ523784A/en not_active IP Right Cessation
- 2001-07-20 JP JP2002513486A patent/JP4928047B2/ja not_active Expired - Fee Related
- 2001-07-20 IL IL15400601A patent/IL154006A0/xx unknown
- 2001-07-20 AU AU2001282004A patent/AU2001282004B2/en not_active Ceased
- 2001-07-20 ES ES01960527T patent/ES2266234T3/es not_active Expired - Lifetime
- 2001-07-20 KR KR1020037000809A patent/KR100864079B1/ko not_active IP Right Cessation
- 2001-07-20 HU HU0300730A patent/HU230151B1/hu not_active IP Right Cessation
-
2003
- 2003-01-10 NO NO20030137A patent/NO329848B1/no not_active IP Right Cessation
- 2003-01-16 IL IL154006A patent/IL154006A/en not_active IP Right Cessation
- 2003-01-20 ZA ZA200300509A patent/ZA200300509B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE50110552D1 (de) | 2006-09-07 |
| AU8200401A (en) | 2002-02-05 |
| HUP0300730A3 (en) | 2010-07-28 |
| US7053049B2 (en) | 2006-05-30 |
| KR20030026980A (ko) | 2003-04-03 |
| WO2002007753A3 (fr) | 2003-02-13 |
| DK1303294T3 (da) | 2006-10-30 |
| DE10035352A1 (de) | 2002-01-31 |
| EP1303294B1 (fr) | 2006-07-26 |
| ES2266234T3 (es) | 2007-03-01 |
| US20040014654A1 (en) | 2004-01-22 |
| EP1303294A2 (fr) | 2003-04-23 |
| IL154006A (en) | 2010-05-31 |
| NO20030137D0 (no) | 2003-01-10 |
| PL204406B1 (pl) | 2010-01-29 |
| NO20030137L (no) | 2003-01-10 |
| HU230151B1 (hu) | 2015-09-28 |
| AU2001282004B2 (en) | 2006-02-02 |
| KR100864079B1 (ko) | 2008-10-16 |
| NZ523784A (en) | 2004-06-25 |
| PL366395A1 (en) | 2005-01-24 |
| JP2004504355A (ja) | 2004-02-12 |
| CA2418238C (fr) | 2012-06-05 |
| ATE333887T1 (de) | 2006-08-15 |
| HUP0300730A2 (hu) | 2003-12-29 |
| KR20070108955A (ko) | 2007-11-13 |
| WO2002007753A2 (fr) | 2002-01-31 |
| NO329848B1 (no) | 2011-01-10 |
| IL154006A0 (en) | 2003-07-31 |
| JP4928047B2 (ja) | 2012-05-09 |
| CA2418238A1 (fr) | 2003-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Isner et al. | Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results | |
| US5230996A (en) | Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation | |
| US7053049B2 (en) | Method for treating unstable angina pectoris | |
| Stewart et al. | Plasma endothelin in coronary venous blood from patients with either stable or unstable angina. | |
| Fujii et al. | Insulin resistance functionally limits endothelium-dependent coronary vasodilation in nondiabetic patients | |
| US11752122B2 (en) | N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated TGF-beta activation and signaling | |
| Morimoto et al. | Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment | |
| JP2004533411A (ja) | 血管形成的に有効なｆｇｆ−２の単位用量および使用方法 | |
| Engelberg et al. | Studies of forearm arteriovenous oxygen differences in atherosclerotic patients before and after heparin | |
| Rademaker et al. | Intravenous captopril treatment in patients with severe cardiac failure. | |
| JP2002524420A (ja) | 脈管形成に有効な単位用量のｆｇｆ−２および使用方法 | |
| EP0532706A1 (fr) | REDUCTION D'OCCLUSIONS DE VAISSEAUX CARDIOVASCULAIRES A L'AIDE D'ASCORBATE ET D'INHIBITEURS DE LIAISON DE LA LIPOPROTEINE (a). | |
| Feldman et al. | Comparison of coronary hemodynamic effects of nitroprusside and sublingual nitroglycerin with anterior descending coronary arterial occlusion | |
| US20230355561A1 (en) | N-acetylcysteine attenuates aortic stenosis progression by inhibiting shear-mediated tgf-beta activation and fibrosis | |
| Shirai et al. | Low serum apolipoprotein AI level in patients with vasospastic angina | |
| Postiglione et al. | Increased blood flow to lower limbs after plasma exchange in two patients with familial hypercholesterolemia | |
| Koeda et al. | Changes in hemodynamics due to the contrast medium during left ventriculography | |
| JP2022510403A (ja) | 虚血傷害および虚血再灌流傷害の予防および／または治療のための方法および組成物 | |
| Putini et al. | Acute coronary syndrome and late stent failure in a patient with Behcet's syndrome | |
| SANBAR et al. | Hypolipidemic effect of polyvinylpyrrolidone in man | |
| Ukai et al. | Improvement in exercise-induced left ventricular dysfunction by infusion of α-human atrial natriuretic peptide in coronary artery disease | |
| JP3691533B2 (ja) | 抗動脈硬化ペプチド | |
| Schwartz et al. | Ceruletide to treat neonatal cholestasis | |
| Sakata et al. | Effects of beraprost sodium, a new prostaglandin I 2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina | |
| FUORTES et al. | Changes in extravascular lung water and fatty acids in a hyperdynamic canine model of sepsis |